Trial Profile
A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Autogene cevumeran (Primary) ; Atezolizumab
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Tumours; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Genentech
- 16 Aug 2023 Planned End Date changed from 29 Sep 2023 to 1 Nov 2024.
- 16 Aug 2023 Planned primary completion date changed from 29 Sep 2023 to 1 Nov 2024.
- 21 Mar 2023 Planned End Date changed from 30 Jun 2023 to 29 Sep 2023.